stockrowANI Pharmaceuticals, Inc. (ANIP) vs Xeris Biopharma Holdings, Inc. (XERS)
- ANI Pharmaceuticals, Inc. ANIP 68.56 −1.52%
- Xeris Biopharma Holdings, Inc. XERS 14.80 +13.15%
ANI Pharmaceuticals, Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Xeris Biopharma Holdings, Inc. is the larger, with a market value of $2.4B against $1.6B — 1.5× the size. Xeris Biopharma Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; ANI Pharmaceuticals, Inc. trades at 13.3×. Xeris Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 38.4% against 25.9%. ANI Pharmaceuticals, Inc. has the higher net margin (11.2% vs −1.76%) and the higher return on invested capital (46.4% vs 27.2%). Across the 20 metrics below, ANI Pharmaceuticals, Inc. leads on 16 and Xeris Biopharma Holdings, Inc. on 4.
Valuation
Profitability
| Metric | ANIP | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 61.06% | 87.38% | 53.51% |
| Operating margin | 15.99% | 12.70% | 0.00% |
| Net margin | 11.22% | (1.76%) | (2.45%) |
| Free cash flow margin | 19.72% | 20.00% | 0.00% |
| Return on equity | 20.45% | (27.11%) | (0.80%) |
| Return on assets | 7.85% | (1.64%) | (1.67%) |
| Return on invested capital | 46.43% | 27.22% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack